Vanessa Research brings cutting-edge science to the world-renowned pediatric congress
Vanessa Research, Inc. (VRI) — a biomedical company that is transforming the healthcare landscape through the development of innovative products and solutions in areas of unmet medical needs — announced it will be a silver sponsor of the 17th Congress of the European Society for Developmental, Perinatal and Paediatric Pharmacology (ESDPPP). The growing start-up will provide critical contributions to the congress as a sponsor and speaker along with other distinguished, multinational corporations. The event will be held May 28-30, 2019 at the Congress Center Basel—the largest conference center in Switzerland.
The primary goal of ESDPPP is to promote research in the field of pediatric pharmacology and to offer a forum for exchange between pharmacologists and clinical physicians about more adequate drug administration. The society’s biennial congress serves as a platform for physicians, pharmacists, nurses, and translational and clinical scientists working in academia, regulatory agencies, and pharmaceutical companies to coalesce on discussions relevant to the science and development of pediatric medicines. ESDPPP is accredited by three societies and works closely with European Medicines Agency (EMA), International Union of Basic and Clinical Pharmacology (IUPHAR), and the World Health Organization (WHO).
On Wednesday, May 29 the Vice President of Research and Development at VRI, Dr. Dmitry Kravtsov, will be presenting on the topic of drug development study design for rare diseases. Kravtsov’s presentation will focus on treatment for the rare, genetic microvillus inclusion disease (MVID). MVID is a pediatric disease for which VRI has been relentlessly working to develop a treatment. Infants with MVID suffer from persistent and severe diarrhea that results in malnutrition, stunted growth, and, in most cases, significantly shortened lifespans. By addressing and raising awareness of this rare disease, VRI promotes its ongoing mission to serve overlooked healthcare markets.
Commenting on his upcoming presentation at the ESDPPP Congress, Kravtsov stated: “This event is another opportunity for VRI to provide a comprehensive analysis and understanding of MVID so that the best treatment options may be developed. Our company plans to continue its global spread of information on this lethal disease, fulfilling our mission to ‘give hope where none existed.’’”
About Vanessa Research
Vanessa Research, Inc. (VRI) is a biomedical company founded on the desire to “give hope where none existed” by making an impact on healthcare markets that are often overlooked. VRI’s continually-expanding pipeline of innovative pharmaceuticals, medical devices, and consumer and public health products reflects the company’s inventive nature and commitment to delivering solutions that increase access to quality care. The company’s flagship product, ShylicineTM, is the first-ever drug developed to treat the rare, lethal microvillus inclusion disease.
VRI is based in Hamden, Connecticut, with offices in Farmington, Connecticut; London, England; Budapest, Hungary; and Navarre, Spain.